The 2009 Stock Conference Report: Inflammation, obesity and metabolic disease

Obesity Reviews

Volumn 11, Issue 9, 2010, Pages 635-644

  Hevener, A L ^a   Febbraio, M A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Inflammation; insulin resistance; metabolic syndrome; obesity

Indexed keywords

DIETHYLNITROSAMINE; INSULIN; LIPID; NUCLEAR RECEPTOR COACTIVATOR 2; SALSALATE;

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW;

COMORBIDITY; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISEASES; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 77956135582     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2009.00691.x     Document Type: Review

References (67)

1. World Health Organization. 2006. Fact Sheet: obesity and overweight WWW document. URL http://www.who.int/mediacentre/factsheets/fs311/en/index.html (accessed November 2009).
2. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006 25 : 3801 3809.
3. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF, Karin M. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004 118 : 285 296.
4. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004 279 : 1304 1309. (Pubitemid 38082655)
5. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005 11 : 1096 1103.
6. Walsh K. Adipokines, myokines and cardiovascular disease. Circ J 2009 73 : 13 18.
7. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008 1 : 36 43.
8. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008 31 : 289 294.
9. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998 1391 : 287 306.
10. Haunerland NH, Spener F. Fatty acid-binding proteins - insights from genetic manipulations. Prog Lipid Res 2004 43 : 328 349.
11. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007 447 : 959 965.
12. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005 1 : 107 119.
13. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008 118 : 2640 2650.
14. Busch AK, Gurisik E, Cordery DV, Sudlow M, Denyer GS, Laybutt DR, Hughes WE, Biden TJ. Increased fatty acid desaturation and enhanced expression of stearoyl coenzyme A desaturase protects pancreatic beta-cells from lipoapoptosis. Diabetes 2005 54 : 2917 2924.
15. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler PC. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007 56 : 2016 2027.
16. Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin AV, Biden TJ. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007 50 : 752 763.
17. Schmitz-Peiffer C, Laybutt DR, Burchfield JG, Gurisik E, Narasimhan S, Mitchell CJ, Pedersen DJ, Braun U, Cooney GJ, Leitges M, Biden TJ. Inhibition of PKCepsilon improves glucose-stimulated insulin secretion and reduces insulin clearance. Cell Metab 2007 6 : 320 328.
18. Poltorak A, Smirnova I, He X, Liu M-Y, Van Huffel C, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EKL, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B. Genetic and physical mapping of the Lps Locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998 24 : 340 355.
19. Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000 275 : 24255 24263.
20. Lang CH, Silvis C, Deshpande N, Nystrom G, Frost RA. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 2003 19 : 538 546.
21. Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006 281 : 26865 26875.
22. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 2008 16 : 1248 1255.
23. Chung J, Nguyen A-K, Henstridge DC, Holmes AG, Chan MHS, Mesa JL, Lancaster GI, Southgate RJ, Bruce CR, Duffy SJ, Horvath I, Mestril R, Watt MJ, Hooper PL, Kingwell BA, Vigh L, Hevener A, Febbraio MA. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 2008 105 : 1739 1744.
24. Nollen EAA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci 2002 115 : 2809 2816.
25. Yamada P, Amorin F, Moseley P, Schneider S. Heat shock protein 72 response to exercise in humans. Sports Med 2008 38 : 715.
26. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes. Diabetes 2003 52 : 2338 2345.
27. McCarty MF. Induction of heat shock proteins may combat insulin resistance. Med Hypotheses 2006 66 : 527 534.
28. Hooper P, Hooper P. Inflammation, heat shock proteins, and type 2 diabetes. Cell Stress Chaperones 2009 14 : 113 115.
29. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Shulman GI, Roden M. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999 42 : 113 116.
30. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999 48 : 1600 1606.
31. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Häring HU. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999 48 : 1113 1119.
32. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006 45 : 42 72.
33. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008 29 : 381 402.
34. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007 5 : 167 179.
35. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003 88 : 2404 2411.
36. Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, Chandler WL, Boyko EJ, Brunzell JD. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009 94 : 1104 1110.
37. Dahlman IA, Vaxillaire MD, Nilsson MB, Lecoeur CD, Gu HFC, Cavalcanti-Proenca CD, Efendic SC, Ostenson CGC, Brismar KC, Charpentier GE, Gustafsson J-A, Froguel PDF, Dahlman-Wright KB, Steffensen KRB. Estrogen receptor alpha gene variants associate with type 2 diabetes and fasting plasma glucose. Pharmacogenet Genomics 2008 18 : 967 975.
38. Yoshihara R, Utsunomiya K, Atsushi Gojo AG, Ishizawa S, Kanazawa Y, Matoba K, Taniguchi K, Yokota T, Kurata H, Yokoyama J-I, Urashima M, Tajima N. Association of polymorphism of estrogen receptora; gene with circulating levels of adiponectin in postmenopausal women with type 2 diabetes. J Atheroscler Thromb 2009 16 : 250 255.
39. Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue H, Ogawa W, Tobimatsu K, Takazawa K, Sakai M, Matsuki Y, Hiramatsu R, Yasuda T, Lazar MA, Yamanashi Y, Kasuga M. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-g phosphorylation. Nat Med 2008 14 : 188 193.
40. Nishino N, Tamori Y, Tateya S, Kawaguchi T, Shibakusa T, Mizunoya W, Inoue K, Kitazawa R, Kitazawa S, Matsuki Y, Hiramatsu R, Masubuchi S, Omachi A, Kimura K, Saito M, Amo T, Ohta S, Yamaguchi T, Osumi T, Cheng J, Fujimoto T, Nakao H, Nakao K, Aiba A, Okamura H, Fushiki T, Kasuga M. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest 2008 118 : 2808 2821.
41. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996 274 : 2100 2103.
42. Sánchez-Lasheras C, Christine Könner A, Brüning JC. Integrative neurobiology of energy homeostasis-neurocircuits, signals and mediators. Front Neuroendocrinol E-pub September 1, 2009. PMID:19729032.
43. Koch L, Wunderlich FT, Seibler J, Könner AC, Hampel B, Irlenbusch S, Brabant G, Kahn CR, Schwenk F, Brüning JC. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest 2008 118 : 2132 2147.
44. Könner AC, Klöckener T, Brüning JC. Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond. Physiol Behav 2009 97 : 632 638.
45. Mesaros A, Koralov SB, Rother E, Wunderlich FT, Ernst MB, Barsh GS, Rajewsky K, Brüning JC. Activation of Stat3 signaling in AgRP neurons promotes locomotor activity. Cell Metab 2008 7 : 236 248.
46. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006 80 : 227 236.
47. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008 111 : 1021 1028.
48. Benrick A, Jirholt P, Wernstedt I, Gustafsson M, Scheller J, Eriksson AL, Boren J, Hedner T, Ohlsson C, Hard T, Rose-John S, Jansson JO. A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regul Pept 2008 146 : 189 196.
49. Carey A, Petersen E, Bruce C, Southgate R, Pilegaard H, Hawley J, Pedersen B, Febbraio M. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 2006 49 : 1000 1007.
50. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006 55 : 2688 2697.
51. Pedersen BK, Febbraio M. Muscle-derived interleukin-6 - a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun 2005 19 : 371 376.
52. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008 88 : 1379 1406.
53. Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argiles JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 2009 296.
54. Matthews VB, Astrom MB, Chan MH, Bruce CR, Krabbe KS, Prelovsek O, Akerstrom T, Yfanti C, Broholm C, Mortensen OH, Penkowa M, Hojman P, Zankari A, Watt MJ, Bruunsgaard H, Pedersen BK, Febbraio MA. Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 2009 52 : 1409 1418.
55. Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH, Pedersen BK, Pilegaard H. Evidence for a release of BDNF from the brain during exercise. Exp Physiol 2009 10 : 1062 1069.
56. Krabbe K, Nielsen A, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer C, Lindegaard B, Petersen A, Taudorf S, Secher N, Pilegaard H, Bruunsgaard H, Pedersen B. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007 50 : 431 438.
57. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A, Wasserman DH. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009 150 : 4084 4093.
58. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett 2008 582 : 3805 3810.
59. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005 115 : 1627 1635.
60. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008 149 : 6018 6027.
61. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett 2008 582 : 1725 1730.
62. Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 2009 58 : 1 7.
63. Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, Walsh K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 2008 283 : 32802 32811.
64. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K. Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 2008 117 : 3099 3108.
65. Nielsen AR, Hojman P, Erikstrup C, Fischer CP, Plomgaard P, Mounier R, Mortensen OH, Broholm C, Taudorf S, Krogh-Madsen R, Lindegaard B, Petersen AM, Gehl J, Pedersen BK. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab 2008 93 : 4486 4493.
66. Nakagawa T, Tsuchida A, Itakura Y, Nonomura T, Ono M, Hirota F, Inoue T, Nakayama C, Taiji M, Noguchi H. Brain-derived neurotrophic factor regulates glucose metabolism by modulating energy balance in diabetic mice. Diabetes 2000 49 : 436 444. (Pubitemid 30131790)
67. Takahashi A, Kureishi Y, Yang J, Luo Z, Guo K, Mukhopadhyay D, Ivashchenko Y, Branellec D, Walsh K. Akt signaling regulates blood vessel recruitment during myofiber growth. Mol Cell Biol 2002 22 : 4803 4814.